Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Tanja D de Gruijl"'
Autor:
Richard van Hillegersberg, Tom van den Ende, Sybren L. Meijer, Rob H.A. Verhoeven, Max Nieuwdorp, Mark P. G. Dings, Nadia Haj Mohammad, Tanja D. de Gruijl, Nicolien C. de Clercq, H.W.M. van Laarhoven, Jacques J. Bergman, Elisabeth D. Geijsen, Stella Mook, Sandor Schokker, Maarten C.C.M. Hulshof, Nicole C.T. van Grieken, Maarten F. Bijlsma, Bauke Ylstra, Jelle P. Ruurda, Mark I. van Berge Henegouwen, Suzanne S. Gisbertz, Tanya T.D. Soeratram
Publikováno v:
van den Ende, T, Clercq, N D, van Berge Henegouwen, M I, Gisbertz, S S, Geijsen, D, Verhoeven, R, Meijer, S L, Schokker, S, Dings, M, Bergman, J J G H M, Haj Mohammad, N, Ruurda, J P, van Hillegersberg, R, Mook, S, Nieuwdorp, M, de Gruijl, T D, Soeratram, T T D, Ylstra, B, van Grieken, N C T, Bijlsma, M F, Hulshof, M C C M & van Laarhoven, H W 2021, ' Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma : A Single Arm Phase II Feasibility Trial (PERFECT) ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 27, no. 12, pp. 3351-3359 . https://doi.org/10.1158/1078-0432.CCR-20-4443
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clinical cancer research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clinical cancer research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clin Cancer Res
Purpose: The CROSS trial established neoadjuvant chemoradiotherapy (nCRT) for patients with resectable esophageal adenocarcinoma (rEAC). In the PERFECT trial, we investigated the feasibility and efficacy of nCRT combined with programmed-death ligand-
Autor:
Iris de Weerdt, Tanja D. de Gruijl, Jurjen M Ruben, Hans van Vliet, Mark-David Levin, Lisa A King, Roeland Lameris, Arnon P. Kater, Paul W. H. I. Parren, Renate de Boer, Jan Kloosterman
Publikováno v:
de Weerdt, I, Lameris, R, Ruben, J M, de Boer, R, Kloosterman, J, King, L A, Levin, M-D, Parren, P W H I, de Gruijl, T D, Kater, A P & van der Vliet, H J 2021, ' A bispecific single-domain antibody boosts autologous Vg9Vd2-T cell responses toward CD1d in chronic lymphocytic leukemia ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 27, no. 6, pp. 1744-1755 . https://doi.org/10.1158/1078-0432.CCR-20-4576
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical cancer research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(6), 1744-1755. AMER ASSOC CANCER RESEARCH
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical cancer research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(6), 1744-1755. AMER ASSOC CANCER RESEARCH
Purpose: Although considerable progress has been made with autologous T cell–based therapy in B-cell malignancies, application in chronic lymphocytic leukemia (CLL) lags behind due to disappointing response rates as well as substantial toxicity tha
Autor:
A. Marijne Heeren, Ekaterina S. Jordanova, Constantijne H. Mom, Maaike C G Bleeker, Henry Zijlmans, Tanja D. de Gruijl, Sinéad M. Lougheed, Anita G.M. Stam, Noëlle Pocorni, Awa A Gassama, G.G. Kenter, Jossie Rotman
Publikováno v:
Clinical Cancer Research, 26(14), 3791-3802. American Association for Cancer Research Inc.
Rotman, J, Heeren, A M, Gassama, A A, Lougheed, S M, Pocorni, N, Stam, A G M, Bleeker, M C G, Zijlmans, H J M A A, Mom, C H, Kenter, G G, Jordanova, E S & de Gruijl, T D 2020, ' Adenocarcinoma of the Uterine Cervix Shows Impaired Recruitment of cDC1 and CD8 + T Cells and Elevated β-Catenin Activation Compared with Squamous Cell Carcinoma ', Clinical Cancer Research, vol. 26, no. 14, pp. 3791-3802 . https://doi.org/10.1158/1078-0432.CCR-19-3826
Clinical cancer research, 26(14), 3791-3802. American Association for Cancer Research Inc.
Rotman, J, Heeren, A M, Gassama, A A, Lougheed, S M, Pocorni, N, Stam, A G M, Bleeker, M C G, Zijlmans, H J M A A, Mom, C H, Kenter, G G, Jordanova, E S & de Gruijl, T D 2020, ' Adenocarcinoma of the Uterine Cervix Shows Impaired Recruitment of cDC1 and CD8 + T Cells and Elevated β-Catenin Activation Compared with Squamous Cell Carcinoma ', Clinical Cancer Research, vol. 26, no. 14, pp. 3791-3802 . https://doi.org/10.1158/1078-0432.CCR-19-3826
Clinical cancer research, 26(14), 3791-3802. American Association for Cancer Research Inc.
Purpose:Adenocarcinoma of the uterine cervix is the second most common type of cervical cancer after squamous cell carcinoma (SCC). Although both subtypes are treated similarly, patients with adenocarcinoma have a worse prognosis. In this study, immu
Autor:
Ronald J.C.L.M. Vuylsteke, Arnold Baars, Alfons J.M. van den Eertwegh, Rik J. Scheper, Tanja D. de Gruijl, Berbel J.R. Sluijter, Mari F.C.M. van den Hout, Bas D. Koster, Paul A. M. van Leeuwen, M. Petrousjka van den Tol, Barbara G. Molenkamp
Publikováno v:
Clinical Cancer Research, 23(19), 5679-5686. American Association for Cancer Research Inc.
Koster, B D, Van Den Hout, M F C M, Sluijter, B J R, Molenkamp, B G, Vuylsteke, R J C L M, Baars, A, Van Leeuwen, P A M, Scheper, R J, Petrousjka van den Tol, M, Van Den Eertwegh, A J M & De Gruijl, T D 2017, ' Local adjuvant treatment with low-dose CpG-B offers durable protection against disease recurrence in clinical stage I–II melanoma : Data from two randomized phase II trials ', Clinical Cancer Research, vol. 23, no. 19, pp. 5679-5686 . https://doi.org/10.1158/1078-0432.CCR-17-0944
Koster, B D, Van Den Hout, M F C M, Sluijter, B J R, Molenkamp, B G, Vuylsteke, R J C L M, Baars, A, Van Leeuwen, P A M, Scheper, R J, Petrousjka van den Tol, M, Van Den Eertwegh, A J M & De Gruijl, T D 2017, ' Local adjuvant treatment with low-dose CpG-B offers durable protection against disease recurrence in clinical stage I–II melanoma : Data from two randomized phase II trials ', Clinical Cancer Research, vol. 23, no. 19, pp. 5679-5686 . https://doi.org/10.1158/1078-0432.CCR-17-0944
Purpose: Although risk of recurrence after surgical removal of clinical stage I–II melanoma is considerable, there is no adjuvant therapy with proven efficacy. Here, we provide clinical evidence that a local conditioning regimen, aimed at immunolog
Autor:
Anita G.M. Stam, Winald R. Gerritsen, Tanja D. de Gruijl, Natalie Sacks, Sinéad M. Lougheed, Thomas Harding, Saskia J. A. M. Santegoets, Israel Lowy, Kristen Hege, Petra E.T. Scholten, Karin Jooss, Alfons J.M. van den Eertwegh, Helen Gall, Rik J. Scheper
Publikováno v:
Clinical Cancer Research. 16:B20-B20
The effects of a GM-CSF-secreting allogeneic prostate cancer vaccine (Prostate GVAX) and the anti-CTLA4 antibody Ipilimumab were investigated in a Phase I dose escalation/expansion trial of patients with metastatic, hormone-refractory prostate cancer